Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.

Torrent management avoided commenting on valuations or whether big-ticket acquisitions are on the cards during a call to discuss fiscal Q2 results, as it faced a volley of questions on the topic following media reports of its interest in acquiring Cipla. Meanwhile, the Brazil business posted handsome gains during the quarter, while the US business shrunk.

Torrent management avoided commenting on valuations or whether big-ticket acquisitions are on the cards during a call to discuss fiscal Q2 results, as it faced a volley of questions on the topic following media reports of its interest in acquiring Cipla. Meanwhile, the Brazil business posted handsome gains during the quarter, while the US business shrunk

A Phase III trial testing subcutaneous nivolumab versus the intravenous product hits pharmacokinetic and efficacy endpoints. BMS, Roche and Merck & Co. all are seeking subcutaneous versions of their anti-PD-1/L1 blockbusters.